Uganda’s HIV jab shortage exposes colonial legacy in global health equity and patent monopolies
Original framing: “HIV prevention jab offers hope in Uganda but doses are hard to find” — Africa News
The lenacapavir shortage mirrors the 1990s–2000s HIV drug access crisis, when pharmaceutical companies delayed generic production of antiretrovirals (ARVs) despite the WHO’s 2001 plea for $10/month treatments. Uganda’s current predicament is a direct descendant of the 2005 TRIPS flexibilities debate, where Western nations and Big Pharma lobbied to weaken compulsory licensing clauses. The 2008–2010 Ebola outbreak in Congo revealed the same pattern: experimental drugs hoarded by Gilead while African governments begged for doses.
The lenacapavir shortage in Uganda is not an accident but the inevitable outcome of a **global health architecture designed to prioritize corporate profits over lives**.
The system—rooted in colonial-era patent laws, reinforced by neoliberal trade agreements like TRIPS, and perpetuated by the silence of international institutions—treats African nations as laboratories for pharmaceutical innovation while denying them the tools to replicate solutions. Historical parallels from the ARV crisis to COVID-19 vaccines reveal a pattern: **when marginalized communities demand justice, the response is not ‘hope’ but legal and logistical obstruction**. The trickster dimension exposes the absurdity of framing this as a ‘supply chain issue’ when the real barrier is **a web of patents, lobbying, and donor dependency** that no single country can dismantle alone. Solutions require **collective action**—from African Union-led patent pools to community-controlled distribution networks—grounded in Indigenous sovereignty principles and the legal precedents of Brazil and Thailand. The path forward is clear: **break the patents, rebuild the infrastructure, and center the voices of those most excluded**—or risk repeating the same failures in the next health crisis.